Chesterfield

“State of Cyber 2021” Brings Together Homeland Security, FBI, Secret Service and Local Executives in St. Louis

Retrieved on: 
Monday, November 29, 2021

ST. LOUIS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Data Connectors, representing the largest cybersecurity community in North America, confirmed the details for the State of Cyber 2021 Conference, which will take place December 1st and 2nd, 2021.

Key Points: 
  • ST. LOUIS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Data Connectors, representing the largest cybersecurity community in North America, confirmed the details for the State of Cyber 2021 Conference, which will take place December 1st and 2nd, 2021.
  • The United States Secret Service is proud to collaborate with our local, state, and federal partners at the State of Cyber 2021 Conference.
  • The two-day agenda represents a combination of the St. Louis Cybersecurity Conference, which has been run annually since 2003, the St. Louis InfraGard Alliances State of Cyber event started in 2016, and an annual update for local cyber professionals conducted by the St. Louis Office of the United States Secret Service Cyber Fraud Task Force.
  • The Conference will take place on Wednesday and Thursday, December 1-2, starting at 8:00 a.m. C.S.T at the Hyatt Regency St. Louis at The Arch, 315 Chestnut St., St. Louis, MO 63102.

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, November 22, 2021

Evercore ISI 4th Annual HealthCONx Conference: Fireside chat on Wednesday, December 1 at 2:00 p.m. E.T.

Key Points: 
  • Evercore ISI 4th Annual HealthCONx Conference: Fireside chat on Wednesday, December 1 at 2:00 p.m. E.T.
  • A webcast of these events, as well as archived recordings, will be available on Avadels Investor Relations website, investors.avadel.com , for 90 days following each conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.
  • Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November

Retrieved on: 
Tuesday, November 9, 2021

DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November:

Key Points: 
  • DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November:
    Stifels 2021 Virtual Healthcare Conference: Fireside chat on Tuesday, November 16 at 8:00 a.m. E.T.
  • Jefferies London Healthcare Conference: Fireside chat available for on demand viewing starting on Thursday, November 18 at 3:00 a.m. E.T.
  • A webcast of these events, as well as archived recordings, will be available on Avadels Investor Relations website, investors.avadel.com , for 90 days following each conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021

ET

Key Points: 
  • ET
    DUBLIN, Ireland, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2021.
  • SG&A expenses were $21.3 million in the quarter ended September 30, 2021, compared to $8.4 million for the same period in 2020.
  • These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events.
  • The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th

Retrieved on: 
Monday, November 1, 2021

ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.

Key Points: 
  • ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.
  • To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International).
  • A live audio webcast can be accessed by visiting the investor relations section of the Companys website, www.avadel.com.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.

Atlanta’s Chief Information Security Officers Debate Future of Cybersecurity; 2022 Trends

Retrieved on: 
Monday, October 25, 2021

The conference features prominent Chief Information Security Officers (CISO) executives from the region, as well as industry luminaries, cybersecurity solutions experts, and representatives from government agencies including the Federal Bureau of Investigation (FBI) and the United States Secret Service.

Key Points: 
  • The conference features prominent Chief Information Security Officers (CISO) executives from the region, as well as industry luminaries, cybersecurity solutions experts, and representatives from government agencies including the Federal Bureau of Investigation (FBI) and the United States Secret Service.
  • The 15th annual event returns with a two-day agenda, highlighting important areas of cybersecurity such as identity and access management, cloud email security, development security operations (DevSecOps), and managed detection and response.
  • He will use these and others to surface lessons learned that translate to what CISOs and all information security executives should regard as best practices.
  • Note to reporters: If you wish to attend these sessions at no charge, please contact Michael Hiskey, Chief Strategy Officer, at +1.636.778.9495, or [email protected].

Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021

Retrieved on: 
Tuesday, October 19, 2021

DUBLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218, also known as ON-SXB. The post-hoc data are being presented in as two separate posters at the American College of Chest Physicians (CHEST) annual meeting, taking place virtually October 17 – 20, 2021, along with the results of a discrete choice experiment (DCE) to understand patient preference. FT218 is the Company’s lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. FT218 is currently under review at the U.S. Food and Drug Administration.

Key Points: 
  • The new post-hoc responder analyses demonstrating that ON-SXB improved EDS provide further confidence in ON-SXB for people with narcolepsy.
  • These ON-SXB data represent a compelling way to set expectations for patients receiving therapy.
  • FT218 has demonstrated meaningful improvement in cataplexy attacks and measurements of EDS with a dosing regimen preferred by patients.
  • We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

State, Local, Federal Cybersecurity Executives Confer on 2022 Threats, Attack Landscape

Retrieved on: 
Monday, October 18, 2021

Over 50,000 professionals focused on information security, risk, and governance have been invited for a Virtual Summit that will debate key issues.

Key Points: 
  • Over 50,000 professionals focused on information security, risk, and governance have been invited for a Virtual Summit that will debate key issues.
  • ), alongside increased focus related to the most recent Executive Order on Cybersecurity.
  • Community members in attendance are also executives at those same concerns, from across the US and Canada.
  • Since 1999, Data Connectors ( dataconnectors.com ) has facilitated collaboration between senior cybersecurity professionals, government/law enforcement agencies, industry luminaries, and solution providers.

Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy

Retrieved on: 
Friday, October 15, 2021

We have not been informed of any deficiencies in our application and remain fully committed to work closely with the FDA for the duration of its review of our NDA for FT218, said Greg Divis, Chief Executive Officer of Avadel.

Key Points: 
  • We have not been informed of any deficiencies in our application and remain fully committed to work closely with the FDA for the duration of its review of our NDA for FT218, said Greg Divis, Chief Executive Officer of Avadel.
  • In February 2021, the FDA accepted Avadels NDA for FT218 and assigned a target action date of October 15, 2021.
  • In March 2020, Avadel completed the REST-ON study, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in patients with narcolepsy.
  • Such forward-looking statements include, but are not limited to, expectations regarding the timing of the FDAs review of the NDA for FT218 and the sufficiency of data supporting the NDA for FT218.

Blue Ridge Bank Announces Its First Electric Vehicle Charging Station Installation

Retrieved on: 
Wednesday, September 22, 2021

(the "Bank"), the national bank subsidiary of Blue Ridge Bankshares, Inc. (NYSE American: BRBS), announces the installation of its first branch electric vehicle charging station, located at 11450 Robious Road, North Chesterfield, Virginia, 23235.

Key Points: 
  • (the "Bank"), the national bank subsidiary of Blue Ridge Bankshares, Inc. (NYSE American: BRBS), announces the installation of its first branch electric vehicle charging station, located at 11450 Robious Road, North Chesterfield, Virginia, 23235.
  • "Blue Ridge Bank supports our local communities while embracing innovation," said Brian K. Plum, President and Chief Executive Officer of Blue Ridge Bank.
  • Blue Ridge Bank partnered with ChargePoint, the world's largest electric vehicle charging network, to install the ChargePoint dual output CT4021 charger.
  • Blue Ridge Bank, N.A., is the wholly owned banking subsidiary of Blue Ridge Bankshares, Inc.